Adjunct ketamine treatment of depression in treatment-resistant schizophrenia patients is unsatisfactory in pilot and secondary follow-up studies.

Chuanjun ZhuoXiaodong LinHongjun TianSha LiuHaiman BianCe Chen

Published in: Brain and behavior (2020)

Depressive symptoms in CTRS-TRD patients were alleviated with adjunct ketamine treatment for only 1 week during the first treatment period. Moreover, after 1 month, the antidepressant effects of ketamine on CTRS-TRD patients completely disappeared. Correspondingly, ReHo alterations induced by ketamine in the CTRS-TRD patients were not maintained for more than 3 weeks. These pilot findings indicate that adjunct ketamine treatment is not satisfactory for CTRS-TRD patients.

Keyphrases

end stage renal disease
ejection fraction
depressive symptoms
chronic kidney disease
newly diagnosed
prognostic factors
clinical trial
chronic pain
preterm birth
case control